BioLife Solutions, Inc. (BLFS) Q1 2026 Earnings Call Transcript
BioLife Solutions, Inc. (BLFS) Q1 2026 Earnings Call Transcript
Seeking Alpha5/8/2026Neutral
BLFS
BioLife Solutions IncNASDAQHEALTHCAREMEDICAL INSTRUMENTS & SUPPLIES
Key Statistics
Market Cap
$1.36B
P/E Ratio
—
EPS
$-0.24
Beta
1.94
52W High
$30.00
52W Low
$17.86
50-Day MA
$24.63
200-Day MA
$24.05
Dividend Yield
—
Profit Margin
-2.91%
Forward P/E
256.41
PEG Ratio
15.09
About BioLife Solutions Inc
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the gene and cell therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company is headquartered in Bothell, Washington.
Fundamentals
| Revenue (TTM) | $101.66M |
| Gross Profit (TTM) | $64.81M |
| EBITDA | $4.32M |
| Operating Margin | 0.10% |
| Return on Equity | -3.09% |
| Return on Assets | -0.09% |
| Revenue/Share (TTM) | $2.11 |
| Book Value | $7.62 |
| Price-to-Book | 3.69 |
| Price-to-Sales (TTM) | 13.42 |
| EV/Revenue | 12.85 |
| EV/EBITDA | 70.89 |
| Quarterly Earnings Growth (YoY) | -13.90% |
| Quarterly Revenue Growth (YoY) | 24.70% |
| Shares Outstanding | $48.86M |
| Float | $42.68M |
| % Insiders | 2.37% |
| % Institutions | 104.51% |
Historical Volatility
HV 10-Day
48.63%
HV 20-Day
48.15%
HV 30-Day
46.35%
HV 60-Day
48.02%
HV Rank
57.5%
Volatility is currently expanding
Analyst Ratings
Consensus ($32.11 target)
1
Strong Buy9
BuyLatest News
4 Medical Product Stocks to Buy From a Challenging Industry
The Zacks Medical - Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. PAHC, BLFS, OMER and BWAY reflect the favorable fundamentals.
Zacks Investment Research4/27/2026Neutral
BioLife Solutions to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
BOTHELL, Wash., April 23, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the 2026 first quarter financial results will be released on May 7, 2026.
PRNewsWire4/23/2026Neutral
BioLife Solutions Wins INTERPHEX 2026 Biotech Innovation Award for CellSeal® CryoCase
Award Recognizes Technologies That Address Important Industry Needs and Advance Prior Standards BOTHELL, Wash., April 21, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced it has received the INTERPHEX 2026 Biotech Innovation Award for its CellSeal® CryoCase, a rigid cryogenic containment system purpose-built for frozen biologic materials.
PRNewsWire4/21/2026Neutral
Wall Street Analysts Think BioLife Solutions (BLFS) Could Surge 70.78%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 70.8% in BioLife Solutions (BLFS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks Investment Research4/8/2026Positive
More HEALTHCARE Stocks
Data last updated: 7/9/2026